British Journal of Clinical Pharmacology

DOI:10.1111/bcp.12334

Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro–con perspective K. Suresh Babu,1 Jack A. Kastelik2,3 & Jaymin B. Morjaria2,3

Correspondence Dr Jaymin B. Morjaria, Department of Academic Respiratory Medicine, Hull York Medical School, Castle Hill Hospital, University of Hull, Cottingham, East Yorkshire HU16 5JQ, UK. Tel.: +44 1482 634892 Fax: +0 1482 624068 E-mail: [email protected] -----------------------------------------------------------------------

Keywords adverse events, budesonide/formoterol, fluticasone/salmeterol, inhaled corticosteroids, mortality, pneumonia -----------------------------------------------------------------------

1

Department of Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, Hampshire, UK, 2Department of Respiratory Medicine, Castle Hill Hospital, Cottingham, East Yorkshire, UK and

Received

3

Accepted

Department of Academic Respiratory Medicine, Castle Hill Hospital, Hull York Medical School, University of Hull, Cottingham, East Yorkshire, UK

15 July 2013 20 January 2014

Accepted Article Published Online 12 February 2014

Current guidelines limit regular use of inhaled corticosteroids (ICS) to a specific subgroup of patients with chronic obstructive pulmonary disease (COPD) in whom the forced expiratory volume in 1 s is 16 000 hip fractures and just